非小细胞肺癌组织中SSTR2A和SSTR5的表达及其临床意义

目的：探讨生长抑素（somatostatin，SST）亚型SSTR2A和SSTR5蛋白在非小细胞肺癌（non-small cell lung cancer，NSCLC）组织中的异常表达及其意义。方法：SP法检测SSTR2A和SSTR5蛋白在62例NSCLC组织和10例癌旁正常肺组织中的表达情况，并进行预后随访。结果：在62例NSCLC组织中，SSTR2A有30例（48．4％）表达阳性；ssTR5有44例（71．0％）表达阳性。SSTR2A、SSTR5蛋白表达与NSCLC的TNM分期密切相关，P=0．014；但与NSCLC患者的年龄、性别、吸烟与否、病理类型和肿瘤大小均无明显相关，P〉0．05。SSTR2A、SSTR5蛋白阳性表达者的3年生存率分别为64．52％和65．91％，阴性表达者为45．16％和22．22％，两者之间差异有统计学意义，P〈0．05。结论：SSTR2A、SSTR5蛋白表达提示NSCLC预后好．生存期长；且与癌恶变程度相关，有可能作为判断NSCLC预后的指标。

Expresssions of SSTR2A and SSTR5 in non-small cell lung cancer and their clinical significance

OBJECTIVE: To study the expressions of somatostatin receptor 2A and somatostatin receptor 5 in human non-small cell lung cancer (NSCLC) and their clinical significance. METHODS: Immunohistochemical staining of SSTR2A and SSTR5 were performed by the standard SP technique for the 62 cases of NSCLC tissues and 10 cases of normal lung tissues nearby the cancer tissues. All the cases were followed up. RESULTS: The positive rate of SSTR2A expression in NSCLC was 48.4%(30/62). The positive rate of SSTR5 expression was 71.0%(44/62). The positive rates of SSTR2A and SSTR5 were related to TNM stage (P=0.014), but not to other clinical characteristics of NSCLC, P>0.05. In the patieyts with SSTR2A and SSTR5 protein-positive expression, the 3-year survival rates were 64.52% and 65.91% respectively, and 45.16% and 22.22% in the ones with negative expression, being significant differences between them, P<0.05. CONCLUSIONS: The patients with the expressions of SSTR2A and SSTR5 have a good prognosis and long survival. The expressions of SSTR2A and SSTR5 are correlated with the malignant degree of lung cancer, and may be of value in the prediction of the prognosis of NSCLC.